Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes

References

• DiazGranados CA, Zimmer SM, Klein M, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41:327–333.
   PubMed Web of Science ®Google Scholar
• Hidron A, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29:996–1011.
   PubMed Web of Science ®Google Scholar
• Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant Enterococcus infection in the United States, 2000–2006. Infect Control Hosp Epidemiol. 2009;30:184–186.
   PubMed Web of Science ®Google Scholar
• Ornstein MC, Mukherjee S, Keng M, et al. Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. Leuk Lymphoma. 2015;56:2536–2542.
   PubMed Web of Science ®Google Scholar
• Worth LJ, Thursky KA, Seymour JF, et al. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol. 2007;79:226–233.
   PubMed Web of Science ®Google Scholar
• Kraft S, Mackler E, Schlickman P, et al. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer. 2011;18:1969–1974.
   Web of Science ®Google Scholar
• Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant Enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transpl. 2007;13:615–621.
   PubMed Web of Science ®Google Scholar
• Avery R, Kalaycio M, Pohlman B, et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant. 2005;25:497–499.
   Web of Science ®Google Scholar
• Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med. 2011;365:892–900.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Humphries R, Uslan DZ, et al. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis. 2011;52:228–234.
   PubMed Web of Science ®Google Scholar
• Kamboj M, Cohen N, Gilhuley K, et al. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol. 2011;32:391–394.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis. 2005;41:565–566.
   PubMed Web of Science ®Google Scholar
• Sabol K, Patterson JE, Lewis JS, et al. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664–1665.
   PubMed Web of Science ®Google Scholar
• Green MR, Anasetti C, Sandin RL, et al. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract. 2006;12:179–181.
   PubMedGoogle Scholar
• Long JK, Choueiri TK, Hall GS, et al. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc. 2005;80:1215–1216.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Humphries R, Uslan DZ, et al. De novo daptomycin-nonsusceptible enterococcal infections. Emerg Infect Dis. 2012;18:674–676.
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Gingrich RD, de Magalhaes Silverman M. Daptomycin nonsusceptible enterococci in hematologic malignancy and hematopoietic stem cell transplant patients: an emerging threat. Ann Hematol. 2013;92:129–131.
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. 2010. CLSI, Wayne, PA, CLSI document M100-S20.
   Google Scholar
• Sader HS, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008). Diagn Microbiol Infect Dis. 2009;65:158–162.
   PubMed Web of Science ®Google Scholar
• Munita JM, Mishra NN, Alvarez D, et al. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring liaSR substitutions. Clin Infect Dis. 2014;59:1277–1280.
   PubMed Web of Science ®Google Scholar
• Storm JC, Diekema DJ, Kroeger JS, et al. Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible Enterococcus. Antimicrob Resist Infect Control. 2012;1:19.
   PubMed Web of Science ®Google Scholar
• Quilitz RE, Jani NK, Velez AP, et al. Vancomycin-resistant and daptomycin-resistant Enterococcus bacteremia and colonization in patients with acute leukemia with prolonged neutropenia. Infect Dis Clin Pract. 2014;22:157–160.
   Google Scholar
• DiPippo AJ, Tverdek FP, Tarrand JJ, et al. Daptomycin non-susceptible Enterococcus faecium in leukemia patients: role of prior daptomycin exposure. J Infect. 2017;74:243–247.
   PubMed Web of Science ®Google Scholar
• Fraher MH, Corcoran GD, Creagh S, et al. Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin. J Hosp Infect. 2007;65:376–378.
   PubMed Web of Science ®Google Scholar
• Shukla BS, Shelburne S, Reyes K, et al. Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint? Clin Infect Dis. 2016;62:1514–1520.
   PubMed Web of Science ®Google Scholar
• Werth BJ, Steed ME, Ireland CE, et al. Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis. Antimicrob Agents Chemother. 2014;58:5253–5261.
   PubMed Web of Science ®Google Scholar
• Hall AD, Steed ME, Arias CA, et al. Evaluation of standard and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2012;56:3174–3180.
   PubMed Web of Science ®Google Scholar
• Soon RL, Turner SJ, Forrest A, et al. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Int J Antimicrob Agents. 2013;42:53–58.
   PubMed Web of Science ®Google Scholar
• Seaton RA, Menichetti F, Dalekos G, et al. Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin® outcomes registry and experience. Adv Ther. 2015;32:1192–1205.
   PubMed Web of Science ®Google Scholar
• King EA, McCoy D, Desai S, et al. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother. 2011;66:2112–2118.
   PubMed Web of Science ®Google Scholar
• Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177–180.
   PubMed Web of Science ®Google Scholar
• Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62:1455–1464.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Benziger DP, Yankelev S, et al. Pharmacokinetics and tolerability of daptomycin at doses of up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245–3249.
   PubMed Web of Science ®Google Scholar
• Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013;57:4190–4196.
   PubMed Web of Science ®Google Scholar
• Lai Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis. 2010;50:737–740.
   PubMed Web of Science ®Google Scholar
• Britt NS, Potter EM, Patel N, et al. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of Veterans Affairs patients. Clin Infect Dis. 2015;61:871–878.
   Google Scholar
• Bio LL, Perez ME, MacDougall C, et al. Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia. Infect Dis Clin Pract. 2011;19:343–347.
   Google Scholar
• Whang DW, Miller LG, Partain NM, et al. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother. 2013;57:5013–5018.
   PubMed Web of Science ®Google Scholar
• Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother. 2014;58:734–739.
   PubMed Web of Science ®Google Scholar